# Biomarkers of Response to Systemic Treatments in FH-deficient RCC

> **NCT05243173** · — · UNKNOWN · sponsor: **RenJi Hospital** · enrollment: 100 (estimated)

## Conditions studied

- Metabolomics
- Renal Cell Carcinoma
- FH-Deficient RCC
- Systemic Treatments

## Interventions

- **OTHER:** Sequencing

## Key facts

- **NCT ID:** NCT05243173
- **Lead sponsor:** RenJi Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-05-25
- **Primary completion:** 2024-06
- **Final completion:** 2024-06
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2022-08-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05243173

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05243173, "Biomarkers of Response to Systemic Treatments in FH-deficient RCC". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05243173. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*